PL2301572T3 - Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego - Google Patents
Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowegoInfo
- Publication number
- PL2301572T3 PL2301572T3 PL10075529T PL10075529T PL2301572T3 PL 2301572 T3 PL2301572 T3 PL 2301572T3 PL 10075529 T PL10075529 T PL 10075529T PL 10075529 T PL10075529 T PL 10075529T PL 2301572 T3 PL2301572 T3 PL 2301572T3
- Authority
- PL
- Poland
- Prior art keywords
- cell
- dna
- cell culture
- low levels
- residual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73278605P | 2005-11-01 | 2005-11-01 | |
EP10075529.7A EP2301572B1 (en) | 2005-11-01 | 2006-11-01 | Cell-derived viral vaccines with low levels of residual cell dna |
EP06831855.9A EP1951296B2 (en) | 2005-11-01 | 2006-11-01 | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2301572T3 true PL2301572T3 (pl) | 2015-02-27 |
Family
ID=37969762
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06831855T PL1951296T5 (pl) | 2005-11-01 | 2006-11-01 | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem |
PL10075529T PL2301572T3 (pl) | 2005-11-01 | 2006-11-01 | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06831855T PL1951296T5 (pl) | 2005-11-01 | 2006-11-01 | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem |
Country Status (19)
Country | Link |
---|---|
US (2) | US10655108B2 (pl) |
EP (3) | EP2301572B1 (pl) |
JP (5) | JP5602366B2 (pl) |
KR (1) | KR20080081254A (pl) |
CN (2) | CN104474543A (pl) |
AT (1) | ATE494906T1 (pl) |
AU (2) | AU2006310171B2 (pl) |
CA (1) | CA2627971A1 (pl) |
CY (1) | CY1111378T1 (pl) |
DE (1) | DE602006019629D1 (pl) |
DK (1) | DK1951296T4 (pl) |
EA (1) | EA014062B1 (pl) |
ES (2) | ES2359214T5 (pl) |
HK (2) | HK1129837A1 (pl) |
NZ (1) | NZ567817A (pl) |
PL (2) | PL1951296T5 (pl) |
PT (1) | PT2301572E (pl) |
SI (1) | SI1951296T2 (pl) |
WO (1) | WO2007052163A2 (pl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ567817A (en) * | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
CA2692200A1 (en) * | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
EP2889042A3 (en) * | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
CA2741961A1 (en) * | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
USH2284H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
AU2010277310B2 (en) | 2009-07-31 | 2015-01-15 | Seqirus UK Limited | Reverse genetics systems |
CN102648003B (zh) | 2009-10-09 | 2016-01-13 | 儿童医疗中心有限公司 | 选择性裂解的全细胞疫苗 |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
ES2562818T3 (es) | 2010-05-03 | 2016-03-08 | Glaxosmithkline Biologicals S.A. | Procedimiento de inactivación del virus de la gripe |
JP6072677B2 (ja) | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
CA2801149A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
SG188947A1 (en) | 2010-08-12 | 2013-06-28 | Yisheng Biopharma Holdings Ltd | Method for reducing dna impurities in viral compositions |
CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
EP2678452B1 (en) | 2011-02-25 | 2016-02-24 | Novartis AG | Exogenous internal positive control for virus detection |
EP3290050B1 (en) | 2011-11-03 | 2019-01-02 | Sentinext Therapeutics SDN BHD | Vaccines directed against human enteroviruses |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
ES2628301T3 (es) | 2012-03-02 | 2017-08-02 | Seqirus UK Limited | Recombinación de virus de gripe |
CA2866465A1 (en) | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Improved vaccination against influenza |
WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
MX2015006927A (es) | 2012-12-03 | 2016-02-05 | Novartis Ag | Redistribucion de virus de la influenza. |
CN111334530A (zh) | 2013-03-13 | 2020-06-26 | 诺华股份有限公司 | 乙型流感病毒重配 |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
BR112015030582A2 (pt) | 2013-06-06 | 2017-08-29 | Novartis Ag | Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão |
CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
CN104513317B (zh) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
ES2817928T3 (es) | 2013-11-15 | 2021-04-08 | Novartis Ag | Eliminación de impurezas de cultivos celulares residuales |
TWI688652B (zh) * | 2014-05-28 | 2020-03-21 | 財團法人國家衛生研究院 | 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造 |
JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
US10416171B2 (en) | 2015-07-07 | 2019-09-17 | Seqirus UK Limited | Influenza potency assays |
EP3184119A1 (en) * | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
CN116407624B (zh) * | 2023-04-14 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
CH589453A5 (pl) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
EP0251575B2 (en) | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
JP2941859B2 (ja) | 1989-09-20 | 1999-08-30 | 国立予防衛生研究所 | Ha蛋白の製造法 |
US5010112A (en) * | 1989-12-01 | 1991-04-23 | Massachusetts Institute Of Technology | Method and apparatus for improving the insulating properties of closed cell foam |
JP3108480B2 (ja) | 1991-09-25 | 2000-11-13 | 松下電工株式会社 | 多重伝送システムの割込処理方法 |
US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
ES2235489T3 (es) * | 1998-06-01 | 2005-07-01 | Chiron Corporation | Uso de polimeros de acido hialuronico para la administracion por las mucosas de antigenos y coadyuvantes de vacunas. |
JP2000230931A (ja) | 1998-12-07 | 2000-08-22 | Katakura Industries Co Ltd | 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット |
DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
AU764368B2 (en) | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
CA2393469A1 (en) | 1999-12-08 | 2001-06-14 | Crucell Holland B.V. | Method of administering adenovirus |
ATE473272T1 (de) | 2000-03-03 | 2010-07-15 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
US20040071734A1 (en) * | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
DE10293048T1 (de) | 2001-04-27 | 2003-07-31 | Glaxosmithkline Biolog Sa | Neuer Impfstoff |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
CN103540568A (zh) * | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
CA2501975A1 (en) | 2002-12-20 | 2004-07-08 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
UA92132C2 (ru) | 2003-05-28 | 2010-10-11 | Висконсин Алюмни Рисьёч Фаундейшн | Высокоактивные рекомбинантные вирусы гриппа для вакцин и генотерапии |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
CA2890962A1 (en) * | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Decreasing potential iatrogenic risks associated with influenza vaccines |
JP4031478B2 (ja) | 2004-12-13 | 2008-01-09 | プロテイン サイエンシーズ | インフルエンザ血球凝集素多価ワクチンの製造方法 |
ES2526170T3 (es) | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
NZ567817A (en) * | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
-
2006
- 2006-11-01 NZ NZ567817A patent/NZ567817A/en not_active IP Right Cessation
- 2006-11-01 WO PCT/IB2006/003880 patent/WO2007052163A2/en active Application Filing
- 2006-11-01 EP EP10075529.7A patent/EP2301572B1/en not_active Revoked
- 2006-11-01 CN CN201410631136.2A patent/CN104474543A/zh active Pending
- 2006-11-01 KR KR1020087013164A patent/KR20080081254A/ko active Search and Examination
- 2006-11-01 CN CN200680046034.8A patent/CN101365480B/zh not_active Expired - Fee Related
- 2006-11-01 EA EA200801221A patent/EA014062B1/ru not_active IP Right Cessation
- 2006-11-01 JP JP2008538454A patent/JP5602366B2/ja active Active
- 2006-11-01 PL PL06831855T patent/PL1951296T5/pl unknown
- 2006-11-01 SI SI200630957T patent/SI1951296T2/sl unknown
- 2006-11-01 EP EP06831855.9A patent/EP1951296B2/en active Active
- 2006-11-01 AT AT06831855T patent/ATE494906T1/de active
- 2006-11-01 AU AU2006310171A patent/AU2006310171B2/en active Active
- 2006-11-01 ES ES06831855.9T patent/ES2359214T5/es active Active
- 2006-11-01 PL PL10075529T patent/PL2301572T3/pl unknown
- 2006-11-01 DE DE602006019629T patent/DE602006019629D1/de active Active
- 2006-11-01 US US12/092,190 patent/US10655108B2/en active Active
- 2006-11-01 EP EP14183359.0A patent/EP2842572A1/en not_active Ceased
- 2006-11-01 ES ES10075529.7T patent/ES2525518T3/es active Active
- 2006-11-01 DK DK06831855.9T patent/DK1951296T4/da active
- 2006-11-01 CA CA002627971A patent/CA2627971A1/en not_active Abandoned
- 2006-11-01 PT PT100755297T patent/PT2301572E/pt unknown
-
2009
- 2009-08-07 HK HK09107245.9A patent/HK1129837A1/xx unknown
-
2011
- 2011-04-05 CY CY20111100356T patent/CY1111378T1/el unknown
- 2011-04-29 AU AU2011201968A patent/AU2011201968B2/en active Active
- 2011-09-21 JP JP2011206634A patent/JP2011256209A/ja not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149517A patent/JP6639077B2/ja active Active
-
2015
- 2015-09-01 HK HK15108523.2A patent/HK1207828A1/xx unknown
-
2016
- 2016-07-25 JP JP2016145286A patent/JP7049761B2/ja active Active
-
2019
- 2019-10-23 JP JP2019192740A patent/JP2020023557A/ja active Pending
-
2020
- 2020-04-09 US US16/843,940 patent/US11466257B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207828A1 (en) | Cell-derived viral vaccines with low levels of residual cell dna dna | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
WO2007024941A3 (en) | Polyvalent vaccine | |
MX2012001592A (es) | Composicion para el tratamiento de la infección del virus de la hepatitis b. | |
WO2012061815A3 (en) | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) | |
MX2012000035A (es) | Antigenos de virus de sincicio respiratorio recombinantes. | |
WO2010019262A3 (en) | Polyvalent vaccine | |
EA200870304A1 (ru) | Псевдоинфекционный флавивирус и его применение | |
WO2004112831A3 (en) | High titer recombinant influenza viruses for vaccines and gene therapy | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
WO2007002470A3 (en) | Inactivated chimeric vaccines and related methods of use | |
WO2011082388A3 (en) | Infectious dna vaccines against chikungunya virus | |
WO2010001409A3 (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
EA201170533A1 (ru) | Высокодиспергируемый диоксид кремния для резин и способ его получения | |
EP1989316A4 (en) | METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS | |
WO2010095041A3 (en) | Compositions, methods, and kits for treating influenza viral infections | |
WO2008048344A3 (en) | Bacillus anthracis antigens, vaccine compositions, and related methods | |
PH12015501378B1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
WO2009080715A3 (en) | Vaccines for malaria | |
WO2008115314A3 (en) | Flavivirus vaccine vector against influenza virus | |
WO2008124176A3 (en) | Soluble and membrane-anchored forms of lassa virus subunit proteins | |
WO2007082734A3 (en) | Influenza vaccine | |
TW200531701A (en) | Method of vaccination against testicular BVDV infection | |
WO2008002152A3 (en) | Process for culturing bacteria of the piscirickettsia genus | |
WO2007028985A3 (en) | Adjuvanted vaccine |